Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 08 04:00PM ET
4.90
Dollar change
+0.04
Percentage change
0.82
%
Index- P/E- EPS (ttm)-0.53 Insider Own- Shs Outstand18.22M Perf Week-10.09%
Market Cap89.62M Forward P/E- EPS next Y-0.64 Insider Trans- Shs Float- Perf Month-29.19%
Income-9.65M PEG- EPS next Q-0.30 Inst Own5.38% Short Float- Perf Quarter10.86%
Sales0.00M P/S- EPS this Y-28.91% Inst Trans-10.61% Short Ratio0.84 Perf Half Y24.15%
Book/sh0.99 P/B4.97 EPS next Y9.39% ROA-38.96% Short Interest0.01M Perf Year-13.88%
Cash/sh0.99 P/C4.95 EPS next 5Y- ROE-42.81% 52W Range2.20 - 7.28 Perf YTD-1.01%
Dividend Est.- P/FCF- EPS past 5Y-24.90% ROI-53.54% 52W High-32.69% Beta0.71
Dividend TTM- Quick Ratio9.30 Sales past 5Y0.00% Gross Margin- 52W Low122.73% ATR (14)0.54
Dividend Ex-Date- Current Ratio9.30 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)47.48 Volatility11.35% 11.65%
Employees14 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price17.01
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q40.36% Payout- Rel Volume1.27 Prev Close4.86
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 28 Avg Volume13.79K Price4.90
SMA20-7.69% SMA504.51% SMA20021.78% Trades Volume17,568 Change0.82%
Date Action Analyst Rating Change Price Target Change
Jun-29-23Resumed ROTH MKM Buy $15
Jul-25-22Initiated H.C. Wainwright Buy $25
Jan-13-22Initiated Maxim Group Buy $21
Oct-23-24 07:00AM
Oct-02-24 06:30AM
Sep-30-24 05:12AM
May-28-24 06:10AM
May-06-24 06:25AM
05:00AM Loading…
Feb-08-24 05:00AM
Sep-06-23 07:00AM
Jul-28-23 03:00AM
Jul-08-23 09:57AM
Jun-29-23 07:00AM
May-17-23 06:34AM
May-16-23 07:00AM
May-09-23 07:15AM
May-02-23 03:30PM
Apr-26-23 07:00AM
07:00AM Loading…
Apr-03-23 07:00AM
Mar-02-23 06:45AM
Feb-07-23 07:00AM
Jan-29-23 07:45AM
Dec-08-22 05:16AM
Nov-07-22 08:05AM
Oct-24-22 07:30AM
Oct-17-22 10:27AM
Oct-05-22 08:05AM
Sep-07-22 07:00AM
Aug-22-22 07:06AM
Jul-25-22 06:00AM
May-27-22 09:40AM
May-13-22 07:30AM
May-09-22 07:30AM
04:30PM Loading…
May-04-22 04:30PM
07:30AM
May-02-22 04:30PM
Apr-27-22 07:30AM
Apr-20-22 07:30AM
Mar-15-22 06:34AM
Mar-09-22 07:46AM
Feb-24-22 07:30AM
Dec-17-21 04:15PM
Dec-14-21 10:36PM
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.